Infectious Disease Phase 2 Deal Benchmarks (2026)

Median upfront of $513M with total deal values reaching $2.7B.

Median Upfront

$513M

Total Deal Value

$2.0B

Royalty Range

7.8%–15.6%

Territory Multiplier

Understanding Infectious Disease Deal Benchmarks at Phase 2

Phase 2 Infectious Disease licensing deals command a median upfront payment of $513M, with values ranging from $295M at the low end to $716M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the infectious disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.4B to $2.7B, with a median of $2.0B. Royalty rates for infectious disease assets at this stage typically fall between 7.8% and 15.6% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Global territory applies a 1x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating global rights should calibrate upfront expectations and milestone structures accordingly.

PRO

Full Market Analysis

Detailed deal economics, territory impact analysis, and royalty structure breakdown.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Full Benchmark Data

PRO

Full Benchmark Table

Low, median, and high ranges for upfront payments, total deal values, and royalty rates.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Comparable Deals

Year	Licensor	Licensee	Upfront	Total Value	Deal Type
2023	Affinivax	GSK	$3.3B	$3.3B	acquisition
2023	Moderna	Merck	$250M	$2.0B	collaboration
2023	Arvinas	Pfizer	$75M	$800M	collaboration
2022	Shionogi	Pfizer	$150M	$800M	licensing
2022	Assembly Biosciences	Roche	$100M	$975M	licensing
2022	Enanta Pharmaceuticals	Novartis	$50M	$780M	licensing
2023	VBI Vaccines	Brii Biosciences	$25M	$200M	licensing
2022	Entasis Therapeutics	Innoviva	$375M	$375M	acquisition
2022	Paratek Pharmaceuticals	N/A (standalone)	$0M	$200M	licensing
2021	Melinta Therapeutics	N/A (standalone)	$0M	$150M	licensing

PRO

See All Comparable Deals

View 10 comparable Infectious Disease transactions with upfront payments, total values, and deal structures.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Frequently Asked Questions

What is the average upfront payment for Phase 2 Infectious Disease deals?

The median upfront payment for Phase 2 Infectious Disease licensing deals is $513M, based on our analysis of comparable transactions. Values range from $295M for early-stage or less differentiated assets up to $716M for premium programs with strong clinical data or first-in-class mechanisms.

How does Global territory affect Infectious Disease deal value?

Global rights carry a 1x multiplier relative to base deal economics. This means global infectious disease deals are valued at a discount compared to single-country rights, reflecting the combined market opportunity, regulatory pathway, and competitive dynamics of the territory.

What royalty rates are typical for Phase 2 Infectious Disease licensing?

Royalty rates for Phase 2 infectious disease assets typically range from 7.8% to 15.6% of net sales. The exact rate depends on the licensor's contribution (IP, clinical data, manufacturing), deal structure (exclusive vs. co-exclusive), and the licensee's commercialization investment. Higher royalties often correspond to lower upfront payments, and vice versa.

PRO

More Expert Insights

Territory impact analysis, royalty negotiation strategies, and deal structure guidance.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

$65M upfront

Infectious Disease · Preclinical · Global

$165M upfront

Infectious Disease · Phase 1 · Global

$1.3B upfront

Infectious Disease · Phase 3 · Global

$3.6B upfront

Infectious Disease · Approved · Global

$258M upfront

Oncology · Phase 2 · Global

$232M upfront

Neurology/CNS · Phase 2 · Global

$547M upfront

Immunology · Phase 2 · Global

$589M upfront

Metabolic/Obesity · Phase 2 · Global

Explore More

All Infectious Disease Deals

View full therapeutic area benchmarks

Licensing Benchmarks Guide

2026 data from 1,900+ deals

Royalty Rate Benchmarks

Negotiation strategies by phase & modality

Run Custom Analysis

Pre-filled with Infectious Disease · Phase 2

Run Your Own Benchmark

These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.

Open Deal Calculator

Cite This Data

APA

Ambrosia Ventures. (2026). Infectious Disease Phase 2 Deal Benchmarks (2026). Retrieved from https://calculator.ambrosiaventures.co/data/infectious-disease-phase-2-deals-global

HTML

<a href="https://calculator.ambrosiaventures.co/data/infectious-disease-phase-2-deals-global">Infectious Disease Phase 2 Deal Benchmarks (2026)</a> — Ambrosia Ventures (2026)

Embed Chart

Data sourced from 1,900+ verified biopharma transactions. Updated monthly.

Metric	Low	Median	High
Upfront Payment	$295M	$513M	$716M
Total Deal Value	$1.4B	$2.0B	$2.7B
Royalty Rate	7.8%	—	15.6%